Amalgamated Financial’s Protagonist Therapeutics PTGX Stock Holding History

Amalgamated Financial’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$173K	Buy	+7,295	New	+$206K	﹤0.01%	1953

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Amalgamated Financial's PTGX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Protagonist Therapeutics (PTGX) in Q1 2022: 7,295 shares worth $173K. The stake represents ﹤0.01% of the portfolio and ranks #1953 among its holdings.

140 funds tracked by Wall St. Rank hold PTGX as of Q1 2022.

Amalgamated Financial held 7,295 shares of Protagonist Therapeutics worth $173K as of Q1 2022.
Protagonist Therapeutics was a new Amalgamated Financial position in Q1 2022.
Protagonist Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1953 holding.
140 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.